FDA approves FET-PET agent for glioma

The radioactive diagnostic drug is indicated in patients aged 1 month or older and is used in conjunction with other diagnostic evaluations.

1

The FDA approved floretyrosine F 18 (Pixclara) for PET imaging to differentiate glioma from treatment-related changes.
2

Floretyrosine F 18 is the first FDA-approved FET-PET imaging drug for glioma, applicable to patients aged 1 month or older.
3

Approximately 24,000 new glioma cases are diagnosed annually in the US, highlighting the need for effective imaging.
4

The safety evaluation of floretyrosine F 18 included 382 patients, with minimal adverse effects reported.
5

PET results from floretyrosine F 18 should be interpreted alongside other clinical information to avoid misinterpretation.

1